Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL944872 | 1.00 | EPHX2 (0.39) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL20591017 | 0.94 | TSHR (0.37) | EPHX2TDP1LMNA | |
| SCHEMBL11241248 | 0.93 | EPHX2 (0.35) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL16742415 | 0.85 | HDAC3 (0.36) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL14482131 | 0.81 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL20450540 | 0.81 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL3251209 | 0.81 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL2380206 | 0.81 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL28706088 | 0.81 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6HDAC8 | |
| SCHEMBL3914424 | 0.81 | EPHX2 (0.49) | EPHX2HDAC1HDAC2HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3192529-B1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | FAULSTICH HEINZ DR (DE) | 2020-03-25 | — | — | EP | disclosed |
| EP-3485912-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | Faulstich, Heinz, Dr. (DE) | 2019-05-22 | — | — | EP | disclosed |
| EP-3192529-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | Faulstich, Heinz, Dr. (DE) | 2017-07-19 | — | — | EP | disclosed |
| EP-2416804-B1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | FAULSTICH HEINZ DR (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-20160089450-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-03-31 | — | — | US | disclosed |
| US-9233173-B2 | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-01-12 | — | — | US | disclosed |
| US-20120100161-A1 | Amatoxin-Armed Therapeutic Cell Surface Binding Components Designed for Tumour Therapy | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100161-A1 | Amatoxin-Armed Therapeutic Cell Surface Binding Components Designed for Tumour Therapy | ANTXR2, TNFSF10, ANXA5 | EPHX2 1265/4885HDAC1 4837/4885HDAC2 4773/4885 |
| US-20160089450-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | ANTXR2, TNFSF10, ANXA5 | EPHX2 1265/4885HDAC1 4837/4885HDAC2 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.